Sun Pharma Advanced Research Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Anilkumar Raghavan

Chief Executive Officer (CEO)

₹69.6m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	10.6yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	7.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Anilkumar Raghavan (56 yo)

10.6yrs

Permanencia

₹69,608,000

Compensación

Mr. Anilkumar Raghavan has been the Chief Executive Officer of Sun Pharma Advanced Research Company Limited since April 24, 2014. Mr. Raghavan is a senior pharmaceutical services executive with significant...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Anilkumar Raghavan	Chief Executive Officer	10.6yrs	₹69.61m	sin datos
Anup Rathi	Chief Financial Officer	less than a year	sin datos	sin datos
Nitin Dharmadhikari	Chief Operating Officer	less than a year	sin datos	sin datos
Jaydeep Issrani	Senior General Manager of Business Development	no data	sin datos	sin datos
Kajal Damania	Company Secretary & Compliance Officer	1.2yrs	sin datos	sin datos
Shanta Gupta	Chief Human Resource Officer	4.8yrs	sin datos	sin datos
Siu-Long Yao	Head Clinical Development	less than a year	sin datos	sin datos
Nitin Damle	Chief Innovation Officer	no data	sin datos	sin datos
Yashoraj Zala	Head of Drug Delivery Systems	no data	sin datos	sin datos
Vikram Ramanathan	Head of Preclinical Development	5.6yrs	sin datos	sin datos
Venkata Palle	Global Head of Drug Discovery & Preclinical Development	1.7yrs	sin datos	sin datos
Shravanti Bhowmik	VP & Head Operations Management	less than a year	sin datos	sin datos

1.2yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 532872 no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Dilip Shanghvi	Chairman	18.7yrs	₹390.00k	19.06% ₹ 12.9b
Robert Jay Spiegel	Independent Director	4.4yrs	₹630.00k	sin datos
Bhavna Doshi	Independent Director	10.1yrs	₹660.00k	sin datos
Thennati Rajamannar	Non-Executive Non-Independent Director	17.4yrs	₹300.00k	0.011% ₹ 7.5m
Vidhi Shanghvi	Additional Non-Executive Non-Independent Director	less than a year	sin datos	sin datos
Ferzaan Engineer	Independent Director	7.5yrs	₹630.00k	sin datos
Mark Simon	Member of Advisory Board	3.9yrs	₹570.00k	sin datos

7.5yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de 532872 se considera experimentada (7.5 años de antigüedad promedio).

Sun Pharma Advanced Research Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Sun Pharma Advanced Research Company Limited Appoints Vidhi Dilip Shanghvi as A Non- Executive, Non-Independent Director

Sun Pharma Advanced Research Company Limited Announces Re-Designation of Nitin Dharmadhikari as Chief Operating Officer

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited Announces Chief Financial Officer Changes

Insufficient new directors

Recent updates

New major risk - Negative shareholders equity

Second quarter 2025 earnings released: ₹3.31 loss per share (vs ₹2.66 loss in 2Q 2024)

New major risk - Revenue and earnings growth

Sun Pharma Advanced Research Company Limited to Report Q2, 2025 Results on Nov 04, 2024

Sun Pharma Advanced Research Company Limited Appoints Vidhi Dilip Shanghvi as A Non- Executive, Non-Independent Director

Sun Pharma Advanced Research Company Limited to Report Q1, 2025 Results on Aug 05, 2024

Sun Pharma Advanced Research Company Limited Announces Re-Designation of Nitin Dharmadhikari as Chief Operating Officer

Full year 2024 earnings released: ₹11.93 loss per share (vs ₹7.82 loss in FY 2023)

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited Announces Chief Financial Officer Changes

Sun Pharma Advanced Research Company Limited to Report Q4, 2024 Results on May 24, 2024

Third quarter 2024 earnings released: ₹3.07 loss per share (vs ₹0.37 profit in 3Q 2023)

Sun Pharma Advanced Research Company Limited to Report Q3, 2024 Results on Feb 05, 2024

Insufficient new directors

Second quarter 2024 earnings released: ₹2.66 loss per share (vs ₹2.52 loss in 2Q 2023)

Sun Pharma Advanced Research Company Limited Announces Retirement of Chitturi Trinadha Rao as Senior Vice President, Drug Discovery

Sun Pharma Advanced Research Company Limited to Report Q2, 2024 Results on Nov 06, 2023

Sun Pharma Advanced Research Company Limited Appoints Kajal Damania as Company Secretary

Sun Pharma Advanced Research Company Limited Announces the Resignation of Mr. Dinesh Lahoti as Company Secretary and Compliance Officer

Sun Pharma Advanced Research Company Limited to Report Q1, 2024 Results on Aug 07, 2023

Full year 2023 earnings released: ₹7.82 loss per share (vs ₹7.73 loss in FY 2022)

Sun Pharma Advanced Research Company Limited Announces That FDA Issues Complete Response Letter for Pdp-716 Nda Due to Inspection Findings At Third-Party Api Manufacturing Facility

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 07, 2023

Full year 2023 earnings released: ₹7.82 loss per share (vs ₹7.73 loss in FY 2022)

Sun Pharma Advanced Research Company Limited to Report Q4, 2023 Results on May 22, 2023

Third quarter 2023 earnings released: EPS: ₹0.37 (vs ₹0.60 loss in 3Q 2022)

Sun Pharma Advanced Research Company Limited to Report Q3, 2023 Results on Feb 13, 2023

Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited Announces U.S. FDA Approval of SEZABY (Phenobarbital Sodium Powder for Injection) for the Treatment of Neonatal Seizures

Second quarter 2023 earnings released: ₹2.52 loss per share (vs ₹2.09 loss in 2Q 2022)

Sun Pharma Advanced Research Company Limited to Report Q2, 2023 Results on Nov 07, 2022

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Sep 22, 2022

First quarter 2023 earnings released: ₹3.03 loss per share (vs ₹2.34 loss in 1Q 2022)

Sun Pharma Advanced Research Company Limited to Report Q1, 2023 Results on Aug 08, 2022

Full year 2022 earnings released: ₹7.73 loss per share (vs ₹5.77 loss in FY 2021)

Sun Pharma Advanced Research Company Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: ₹2.09 loss per share (vs ₹3.19 loss in 2Q 2021)

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

First quarter 2022 earnings released: ₹2.34 loss per share (vs ₹2.16 profit in 1Q 2021)

Full year 2021 earnings released: ₹5.77 loss per share (vs ₹11.92 loss in FY 2020)

Sun Pharma Advanced Research Company Ltd. Reports Positive Top-Line Results from Its Phase 3 Trial for Its Investigational Drug

Sun Pharma Advanced Research Company Limited announced that it expects to receive INR 3.002424034 billion in funding from a group of investors

Sun Pharma Advanced Research Company Limited Announces the U.S. Food and Drug Administration Deny Appeal of the Complete Response Letter

New 90-day low: ₹173

Third quarter 2021 earnings released: ₹2.58 loss per share (vs ₹2.12 loss in 3Q 2020)

Sun Pharma Advanced Research Company Limited to Report Q3, 2021 Results on Feb 08, 2021

New 90-day high: ₹194

New 90-day high: ₹185

Second quarter 2021 earnings released: ₹3.19 loss per share

Sun Pharma Advanced Research Company Limited to Report Q2, 2021 Results on Nov 09, 2020

New 90-day low: ₹165

Sun Pharma Advanced Research Company Limited Announces the Grant of an Exclusive License to Tripoint Therapeutics Llc, USA (Tripoint) to Commercialize Elepsia Xr 1000 Mg and Elepsia Xr 1500 Mg Tablets

New 90-day high - ₹190

First quarter earnings released

Sun Pharma Advanced Research Company Limited to Report Q1, 2021 Results on Aug 04, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta